Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin.

Cell reports - 26 Dec 2023

Guo Yanguan, Tian Jiaxin, Guo Yongjian, Wang Cong, Chen Congcong, Cai Songwang, Yu Wenliang, Sun Binghe, Yan Jin, Li Zhonghua, Fan Jun, Qi Qi, Zhang Dongmei, Jin Weilin, Hua Zichun, Chen Guo

Abstract excerpt

KRAS mutations are frequently detected in non-small cell lung cancers (NSCLCs). Although covalent KRASG12C inhibitors have been developed to treat KRASG12C-mutant cancers, effective treatments are still lacking for other KRAS-mutant NSCLCs. Thus, identifying a KRAS effector that confers poor prognosis would provide an alternative strategy for the treatment of KRAS-driven cancers. Here, we show that KRAS drives...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Ubiquitin-Specific Proteases

Source

Identifiers

PMID: 38043062
DOI: 10.1016/j.celrep.2023.113511

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin.PMID 38043062Read ↗

USP7 deubiquitinates KRAS and promotes non-small cell lung cancer.Semantic proximity Read ↗

Targeting USP13 ‐mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non‐small cell lung cancerSemantic proximity Read ↗

Targeting USP47 enhances the efficacy of KRAS inhibitor in KRASG12C mutated non-small cell lung cancer by controlling deubiquitination of c-Myc.Semantic proximity Read ↗

Over-Expression of Deubiquitinating Enzyme USP14 in Lung Adenocarcinoma Promotes Proliferation through the Accumulation of β-CateninSemantic proximity Read ↗

Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer.Semantic proximity Read ↗

USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer.Semantic proximity Read ↗

USP5-Beclin 1 axis overrides p53-dependent senescence and drives Kras-induced tumorigenicity.Semantic proximity Read ↗

USP13: Multiple Functions and Target InhibitionSemantic proximity Read ↗

USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancerSemantic proximity Read ↗

USP48 stabilizes YBX1 to enforce a Wnt-driven stemness circuit and osimertinib resistance in EGFR-mutant NSCLC.Semantic proximity Read ↗

Ubiquitin-specific protease 11 serves as a marker of poor prognosis and promotes metastasis in hepatocellular carcinomaSemantic proximity Read ↗

USP14 Inhibition Regulates Tumorigenesis by Inducing Autophagy in Lung Cancer In VitroSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.